Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398801 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1398687 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1398708 | 0.94 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1398584 | 0.81 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL1398546 | 0.79 | HCRTR1 (0.45) | HCRTR1HCRTR2RAB9A | |
| SCHEMBL1398698 | 0.78 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1398628 | 0.78 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1398579 | 0.78 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1398554 | 0.77 | HCRTR1 (0.43) | HCRTR1HCRTR2OPRM1 | |
| SCHEMBL6820366 | 0.73 | HCRTR1 (0.59) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | HCRTR1, HCRTR2, OXTR | HCRTR1 1/4885HCRTR2 2/4885OPRM1 198/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | HCRTR1 18/4885HCRTR2 14/4885OPRM1 108/4885 |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | GPR180, OXGR1, MLNR | HCRTR1 22/4885HCRTR2 17/4885OPRM1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.